SAT1 and familial pancreatic carcinoma: Furthermore, stratification of survival data of patients with pancreatic cancer based on SAT1 expression showed a significantly lower overall survival in patients with high SAT1 expression (median survival, 498 days) as compared to patients with low SAT1 expression (median survival, 1,332 days) (Fig. 7h).